These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 1111247)

  • 1. [Mechanism of action of desferrioxamine].
    Kaszewska-Jablońska I; Zielińska W
    Wiad Lek; 1975 Jan; 28(2):89-96. PubMed ID: 1111247
    [No Abstract]   [Full Text] [Related]  

  • 2. [Effect of desferrioxamine B and 2-(beta-aminoethoxy)cyclohexylaminetetraacetate in experimental hemochromatosis in rats and in primary hemochromatosis of man].
    Bohne F; Lessmann J
    Arzneimittelforschung; 1969 Jun; 19(6):944-7. PubMed ID: 5820039
    [No Abstract]   [Full Text] [Related]  

  • 3. Studies on iron metabolism with desferrioxamine in man. Experimental and clinical studies.
    Hedenberg L
    Scand J Haematol Suppl; 1969; 6():5-86. PubMed ID: 5259199
    [No Abstract]   [Full Text] [Related]  

  • 4. Neonatal hemochromatosis: failure of deferoxamine therapy.
    Jonas MM; Kaweblum YA; Fojaco R
    J Pediatr Gastroenterol Nutr; 1987; 6(6):984-8. PubMed ID: 3681586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary excretion of uric acid in iron deficient rats.
    Sharma DC; Simlot MM
    Indian J Exp Biol; 1982 Dec; 20(12):911-2. PubMed ID: 6897838
    [No Abstract]   [Full Text] [Related]  

  • 6. [Mechanism of action and role of xanthine oxidoreductases (author's transl)].
    Jezewska MM
    Postepy Biochem; 1974; 20(3):259-79. PubMed ID: 4849147
    [No Abstract]   [Full Text] [Related]  

  • 7. [Xanthine-oxidoreductase (E.C.1.2.3.2.) activity in riboflavin or thiamine deficient rat liver].
    Feldheim W; Gazo M
    Int J Vitam Nutr Res; 1971; 41(2):221-30. PubMed ID: 4329103
    [No Abstract]   [Full Text] [Related]  

  • 8. [Contribution to the problem of hemochromatosis].
    Bruns W; Michaelis D; Takác A; Langsch HG
    Dtsch Z Verdau Stoffwechselkr; 1966 Feb; 25(6):363-70. PubMed ID: 5998360
    [No Abstract]   [Full Text] [Related]  

  • 9. [Therapeutic results in the treatment of primary and secondary hemochromatoses with Desferal].
    Wöhler F
    Blut; 1967 Apr; 15(1):33-42. PubMed ID: 6025965
    [No Abstract]   [Full Text] [Related]  

  • 10. Desferal therapy in iron storage disease.
    Thompson RB; Owen DM; Bell WN
    Am J Med Sci; 1967 Apr; 253(4):453-60. PubMed ID: 6021380
    [No Abstract]   [Full Text] [Related]  

  • 11. [Demonstration of increased iron storage in the organism with desferrioxamine (desferal test)].
    Schnack H; Wewalka F
    Med Welt; 1965 Jul; 27():1529-35. PubMed ID: 5838535
    [No Abstract]   [Full Text] [Related]  

  • 12. Subcutaneous desferrioxamine: the effect of three years' treatment on liver, iron, serum ferritin, and comments on echocardiography.
    Flynn DM; Hoffbrand AV; Politis D
    Birth Defects Orig Artic Ser; 1982; 18(7):347-53. PubMed ID: 6819017
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term intraperitoneal deferoxamine for hemochromatosis.
    Swartz RD; Legault DJ
    Am J Med; 1996 Mar; 100(3):308-12. PubMed ID: 8629676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of the ion-exchange resin desferrioxamine B on iron metabolism].
    Keler-Bacoka M; Hahn A
    Lijec Vjesn; 1965 Dec; 87(12):1329-38. PubMed ID: 5880072
    [No Abstract]   [Full Text] [Related]  

  • 15. [Nocturanl paroxysmal hemoglobinuria. II. Renal insufficiency in the course of the same (clinical, histological and ultramicroscopic study of the renal pathology and of its development after desferrioxamine therapy)].
    Tejero Lamarca J; Yangüela Terroba J; Diáz-Flores L
    Rev Clin Esp; 1973 Feb; 128(4):287-98. PubMed ID: 4700581
    [No Abstract]   [Full Text] [Related]  

  • 16. Desferrioxamine therapy induces clearance of iron deposits after bone marrow transplantation for thalassemia: case report.
    Giardini C; La Nasa G; Contu L; Galimberti M; Polchi P; Angelucci E; Baronciani D; Barbanti I; Muretto P; Lucarelli G
    Bone Marrow Transplant; 1993; 12 Suppl 1():108-10. PubMed ID: 8374548
    [No Abstract]   [Full Text] [Related]  

  • 17. [Diagnostic value of some iron metabolic parameters in acute and chronic liver diseases].
    Scuro LA
    Quad Sclavo Diagn; 1971 Dec; 7(4):1302-23. PubMed ID: 5161744
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of allopurinol on iron mobilization.
    Grace ND; Greenwald MA; Greenberg MS
    Gastroenterology; 1970 Jul; 59(1):103-8. PubMed ID: 5426980
    [No Abstract]   [Full Text] [Related]  

  • 19. [Yersinia enterocolitica septicemia associated with idiopathic hemochromatosis and deferoxamine therapy. A case].
    Nouel O; Voisin PM; Vaucel J; Dartois-Hoguin M; Le Bris M
    Presse Med; 1991 Oct; 20(31):1494-6. PubMed ID: 1835044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Use of desferrioxamine B in normal subjects and in patients with increased iron storage].
    Muranda M; Velasco M; Giménez E; Ruiz J; Bastías E; Rodriguez J; Etcheverry R; Guzmán C; Regonesi C; Janklevich S
    Rev Med Chil; 1965 Apr; 93(4):127-33. PubMed ID: 5832943
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.